TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis

被引:43
作者
Cruz-Muñoz, W
Kim, I
Khokha, R
机构
[1] Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
TIMP-3; host stroma; B16F10; teratoma; angiogenesis;
D O I
10.1038/sj.onc.1209104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3(-/-) ES-cell clones were generated and used to develop teratomas in nude mice. Timp-3(-/-) teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3(-/-) teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3(-/-) and wildtype littermates. Tumors grew significantly faster in timp3(-/-) than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3(-/-) mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3(-/-) endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 46 条
[11]   Promoter hypermethylation profile of kidney cancer [J].
Dulaimi, E ;
Ibanez de Caceres, I ;
Uzzo, RG ;
Al-Saleem, T ;
Greenberg, RE ;
Polascik, TJ ;
Babb, JS ;
Grizzle, WE ;
Cairns, P .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :3972-3979
[12]   Accelerated apoptosis in the Timp-3-deficient mammary gland [J].
Fata, JE ;
Leco, KJ ;
Voura, EB ;
Yu, HYE ;
Waterhouse, P ;
Murphy, G ;
Moorehead, RA ;
Khokha, R .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (06) :831-841
[13]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18
[14]  
Itoh T, 1998, CANCER RES, V58, P1048
[15]   Combination of tumor necrosis factor-α ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice [J].
Kassiri, Z ;
Oudit, GY ;
Sanchez, O ;
Dawood, F ;
Mohammed, FF ;
Nuttall, RK ;
Edwards, DR ;
Liu, PP ;
Backx, PH ;
Khokha, R .
CIRCULATION RESEARCH, 2005, 97 (04) :380-390
[16]   Diminished corneal angiogenesis in gelatinase A-deficient mice [J].
Kato, T ;
Kure, T ;
Chang, JH ;
Gabison, EE ;
Itoh, T ;
Itohara, S ;
Azar, DT .
FEBS LETTERS, 2001, 508 (02) :187-190
[17]   Matrix metalloproteinases and metastasis [J].
Kleiner, DE ;
Stetler-Stevenson, WG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (Suppl 1) :S42-S51
[18]   Altered tumor growth and metastasis of a T-Cell lymphoma in timp-1 transgenic mice [J].
Kruger, A ;
Fata, JE ;
Khokha, R .
BLOOD, 1997, 90 (05) :1993-2000
[19]   Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3) [J].
Leco, KJ ;
Waterhouse, P ;
Sanchez, OH ;
Gowing, KLM ;
Poole, AR ;
Wakeham, A ;
Mak, TW ;
Khokha, R .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (06) :817-829
[20]   Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 [J].
Leighl, NB ;
Paz-Ares, L ;
Douillard, JY ;
Peschel, C ;
Arnold, A ;
Depierre, A ;
Santoro, A ;
Betticher, DC ;
Gatzemeier, U ;
Jassem, J ;
Crawford, J ;
Tu, DS ;
Bezjak, A ;
Humphrey, JS ;
Voi, M ;
Galbraith, S ;
Hann, K ;
Seymour, L ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2831-2839